Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”

Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC


Sign up for our daily newsletter


DePuy Synthes gets additional FDA clearance for spine systems in adolescent scoliosis surgery

9:24 pm by | 0 Comments

DePuy Synthes Viper2

Johnson & Johnson’s (NYSE:JNJ) DePuy Synthes Spine is expanding its reach in the spine market with U.S. Food and Drug Administration clearance of three of its systems for use in adolescents with scoliosis undergoing posterior noncervical pedicle screw fixation.

The Expedium, Viper and Viper 2 spine systems, which are already cleared for use in adults, received the additional 510(k) clearance last month, the company said today. The Viper and Viper 2 have been used in minimally invasive spine surgeries since 2005 and 2008, respectively, and the Expedium 4.5 Spine System for use in small statue patients was launched in 2008.

An estimated 30,000 children with adolescent idiopathic scoliosis are fitted with a brace each year, according to the National Scoliosis Foundation. Those with a spine curvature that exceeds 45 degrees may be recommended for spinal fusion surgery, in which pedicle screws are often used in conjunction with autograft or allograft to affix rods to the spine.

Advertisement

J&J’s competitor Medtronic (NYSE:MDT) was first to receive FDA clearance of a pedicle screw system to treat adolescent idiopathic scoliosis in December of 2010 and also received clearance for its TSRH Spinal System for use in adolescents in September of last year. But DePuy Synthes has previously addressed the adolescent spine market with a saliva-based genetic test, ScoliScore, developed by Axial Biotech to predict the risk of curve progression in children ages 9 through 13 diagnosed with AIS.

DePuy, which generated sales of $5.8 billion in 2011, acquired skeletal fixation company Synthes Inc. for $19.7 billion in April of last year.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Deanna Pogorelc

By Deanna Pogorelc MedCity News

Deanna Pogorelc is a Cleveland-based reporter who writes obsessively about life science startups across the country, looking to technology transfer offices, startup incubators and investment funds to see what’s next in healthcare. She has a bachelor’s degree in journalism from Ball State University and previously covered business and education for a northeast Indiana newspaper.
More posts by Author

0 comments

Hear the latest news first

Get our daily newsletter or follow us.

 

Advertisement